Matthew L Smith

Summary

Affiliation: Cancer Research UK
Country: UK

Publications

  1. ncbi Mutation of CEBPA in familial acute myeloid leukemia
    Matthew L Smith
    Medical Oncology Unit, Cancer Research UK, Barts and the London School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London
    N Engl J Med 351:2403-7. 2004
  2. ncbi Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3
    Matthew L Smith
    Cancer Research UK Medical Oncology Unit, Charterhouse Square, Barts and the London School of Medicine and Dentistry, London
    Br J Haematol 128:318-23. 2005
  3. ncbi Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
    Jennifer Snaddon
    Cancer Research UK Medical Oncology Unit, Charterhouse Square, St Bartholomew s Hospital, London, United Kingdom
    Genes Chromosomes Cancer 37:72-8. 2003
  4. ncbi Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia
    Lan-Lan Smith
    Br J Haematol 133:103-5. 2006

Collaborators

  • Dominique Bonnet
  • Lan-Lan Smith
  • T Andrew Lister
  • Jude Fitzgibbon
  • Jennifer Snaddon
  • Lindsey Goff
  • Michael Jenner
  • Daniel Pearce
  • John A Amess
  • Rachael Arch
  • Amanda Dixon-McIver
  • Ama Z Rohatiner
  • Maxine Cambal-Parrales
  • Michael Neat

Detail Information

Publications4

  1. ncbi Mutation of CEBPA in familial acute myeloid leukemia
    Matthew L Smith
    Medical Oncology Unit, Cancer Research UK, Barts and the London School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London
    N Engl J Med 351:2403-7. 2004
    ..All three patients are currently well, with no abnormalities in the bone marrow. CEBPA mutation is apparently the primary event in the development of AML in this family...
  2. ncbi Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3
    Matthew L Smith
    Cancer Research UK Medical Oncology Unit, Charterhouse Square, Barts and the London School of Medicine and Dentistry, London
    Br J Haematol 128:318-23. 2005
    ..A 51-bp deletion was detected in CCND3 in a patient with normal karyotype AML. This validated panel now provides an important tool to evaluate other candidate genes in the genesis of myeloid malignancy...
  3. ncbi Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2
    Jennifer Snaddon
    Cancer Research UK Medical Oncology Unit, Charterhouse Square, St Bartholomew s Hospital, London, United Kingdom
    Genes Chromosomes Cancer 37:72-8. 2003
    ..In conclusion, mutation of CEBPA is a recurrent finding in AML and appears specific to the intermediate cytogenetic risk group patients...
  4. ncbi Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemia
    Lan-Lan Smith
    Br J Haematol 133:103-5. 2006